Propanc Biopharma (PPCB) Tax Provisions (2010 - 2024)
Propanc Biopharma (PPCB) posted quarterly Tax Provisions of -$237.0 for Q2 2024, down 119.82% year-over-year from $1196.0 in Q3 2023, and up 13.82% quarter-over-quarter from -$275.0 in Q1 2024.
Propanc Biopharma (PPCB) Tax Provisions (2010 - 2024) Analysis & Trends
Propanc Biopharma (PPCB) has reported Tax Provisions for 15 consecutive years, with -$237.0 the latest figure, recorded in Q2 2024.
- In Q2 2024, Tax Provisions fell 119.82% year-over-year to -$237.0; the TTM figure through Jun 2024 stood at -$127936.0 (up 1.26% YoY), while the FY2024 annual figure was -$129132.0, up 0.55% from the prior year.
- Tax Provisions rose to -$237.0 in Q2 2024 per PPCB's latest filing, from -$275.0 in the prior quarter.
- Across five years, Tax Provisions topped out at $1196.0 in Q2 2023 and bottomed at -$129321.0 in Q4 2022.
- Historically, Tax Provisions has averaged -$34872.5 across 5 years, with a median of -$1138.0 in 2021.
- Annual changes were most pronounced in 2020 — Tax Provisions tumbled 3724.93% — and 2023, when it jumped 338.1%.
- Propanc Biopharma's Tax Provisions stood at $340.0 in 2020, then slumped by 16412.65% to -$55463.0 in 2021, then sank by 133.17% to -$129321.0 in 2022, then gained by 0.54% to -$128620.0 in 2023, then jumped by 99.82% to -$237.0 in 2024.
- Business Quant data shows PPCB's Tax Provisions at -$237.0 in Q2 2024, -$275.0 in Q1 2024, and -$128620.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 59.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 15.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 75.45 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 13.31 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.90 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -90.33 Mn |
| 10 | Propanc Biopharma | 587,855.41 | 587,855.41 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -237.00 |
| Mar 31, 2024 | -275.00 |
| Dec 31, 2023 | -128,620.00 |
| Jun 30, 2023 | 1,196.00 |
| Mar 31, 2023 | -1,716.00 |
| Dec 31, 2022 | -129,321.00 |
| Jun 30, 2022 | 273.00 |
| Mar 31, 2022 | 213.00 |
| Dec 31, 2021 | -55,463.00 |
| Jun 30, 2021 | -1,138.00 |
| Mar 31, 2021 | -112,277.00 |
| Jun 30, 2020 | 340.00 |
| Mar 31, 2020 | -26,317.00 |
| Dec 31, 2019 | 143.00 |
| Sep 30, 2019 | -108,894.00 |
| Jun 30, 2019 | -1.09 Mn |
| Mar 31, 2019 | 726.00 |
| Dec 31, 2018 | -116,970.00 |
| Jun 30, 2018 | 1,457.00 |
| Mar 31, 2018 | -485.00 |